AstraZeneca & Merck Reports P-III SOLO-1 Trial Results of Lynparza (olaparib) for 1L+ Treatement in Advance BRCAm Ovarian Cancer at ESMO18

 AstraZeneca & Merck Reports P-III SOLO-1 Trial Results of Lynparza (olaparib) for 1L+ Treatement in Advance BRCAm Ovarian Cancer at ESMO18

AstraZeneca & Merck Reports P-III SOLO-1 Trial Results of Lynparza (olaparib) for 1L+ Treatement in Advance BRCAm Ovarian Cancer at ESMO18

Shots:

  • The P-III SOLO-1 Trial includes assessing of Lynparza (olaparib) (300mg bid) vs PBO in 391 patients in ratio (2:1) with newly-diagnosed, BRCA1/2 mutation who were in CR or PR following 1L Pt-based CT
  • P-III SOLO-1 Trial results: reduction in risk of disease progression or death by 70%; PFS @ 36 mos. (60% vs 27%); mPFS for Lynparza didn’t reached 13.8 months as for PBO
  • Lynparza (olaparib) is a novel PARPi, used in 20,000 patients worldwide and is approved for advanced OC and mBC. In July 2017, AZ & Merck globally collaborated to co-develop and co-commercialise Lynparza

Click here to read full press release/ article | Ref: Astrazeneca | Image: Wall Street Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post